{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:42:31Z","timestamp":1791463351164,"version":"4.3.4"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 73-year-old woman with history of metastatic basal cell carcinoma presented with a large spinal mass demonstrating a high mutational burden of 111 mutations\/Mb. She underwent T12 corpectomy and T10\u2013L3 posterior spinal fusion followed by adjuvant radiation. After 2 years of surveillance, FDG PET\/CT and a contrast-enhanced MRI revealed recurrence, prompting salvage therapy with the hedgehog signaling pathway inhibitor, sonidegib, which only transiently stabilized the disease. An off-label treatment with the programmed death protein 1 inhibitor, pembrolizumab, was initiated. Serial FDG PET\/CT showed gradual decline in tumor metabolism over the next 12 months, leading to complete metabolic response.<\/jats:p>","DOI":"10.1097\/rlu.0000000000003528","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T05:22:48Z","timestamp":1611897768000},"page":"e436-e437","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["18F-FDG PET\/CT Monitoring of Response to Programmed Death Protein 1 Blockade in Metastatic Basal Cell Carcinoma"],"prefix":"10.1097","volume":"46","author":[{"given":"Hossein","family":"Jadvar","sequence":"first","affiliation":[{"name":"Department of Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gino K.","family":"In","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,2,3]]},"reference":[{"key":"bib1-20250621","first-page":"157187","article-title":"Metastatic basal cell carcinoma: a biological continuum of basal cell carcinoma?","volume":"2012","year":"2012","journal-title":"Case Rep Dermatol Med"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejca.2019.06.003","article-title":"Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines","volume":"118","year":"2019","journal-title":"Eur J Cancer"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1093\/annonc\/mdy412","article-title":"Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics","volume":"29","year":"2018","journal-title":"Ann Oncol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","year":"2012","journal-title":"N Engl J Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40425-017-0228-3","article-title":"Basal cell carcinoma: PD-L1\/PD-1 checkpoint expression and tumor regression after PD-1 blockade","volume":"5","year":"2017","journal-title":"J Immunother Cancer"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jamadermatol.2016.5062","article-title":"Association between programmed death ligand 1 expression in patients with basal cell carcinomas and the number of treatment modalities","volume":"153","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"suppl 4","key":"bib7-20250621","first-page":"S1142","article-title":"LBA47\u2014primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs)","volume":"31","year":"2020","journal-title":"Ann Oncol"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/cam4.33","article-title":"18-FDG PET\/CT assessment of basal cell carcinoma with vismodegib","volume":"1","year":"2012","journal-title":"Cancer Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003528","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T21:03:10Z","timestamp":1750539790000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,3]]},"references-count":8,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003528","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,3]]}}}